Beam Therapeutics achieves top CGT award for BEAM-302

Beam Therapeutics achieves top CGT award for BEAM-302
@BeamTx: Beam wins BioTech award

Beam Therapeutics has been awarded the Overall CGT Solution of the Year for its alpha-1 antitrypsin deficiency program, BEAM-302.

This recognition comes from the esteemed BioTech Awards, highlighting Beam's innovative contributions to the field. The BEAM-302 program focuses on addressing genetic disorders through precise genetic editing techniques.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.